BTIG analyst Kaveri Pohlman maintained a Buy rating on Sonnet BioTherapeutics Holdings (SONN – Research Report) yesterday and set a price target of $2.00. The company’s shares opened today at $1.74.
Pohlman covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Genmab, and Ambrx Biopharma. According to TipRanks, Pohlman has an average return of -11.6% and a 32.50% success rate on recommended stocks.
Currently, the analyst consensus on Sonnet BioTherapeutics Holdings is a Moderate Buy with an average price target of $4.50.
See the top stocks recommended by analysts >>
The company has a one-year high of $36.96 and a one-year low of $1.08. Currently, Sonnet BioTherapeutics Holdings has an average volume of 75.23K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sonnet BioTherapeutics Holdings (SONN) Company Description:
Sonnet BioTherapeutics (NASDAQ:SONN) is a clinical-stage biotechnology company that is focused on the development of drugs for the treatment of cancer.
Read More on SONN:
